Last update 12 Dec 2024
HRS-4642
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms HRS 4642, HRS4642 |
Target |
Mechanism KRAS G12D inhibitors(GTPase KRas G12D inhibitors) |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
11
Clinical Trials associated with HRS-4642A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in Patients with Advanced Biliary Tract Tumors.
An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for the Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
A Single-center, Open-label, Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
100 Clinical Results associated with HRS-4642
Login to view more data
100 Translational Medicine associated with HRS-4642
Login to view more data
100 Patents (Medical) associated with HRS-4642
Login to view more data
2
Literatures (Medical) associated with HRS-464201 Jul 2024CANCER CELL
HRS-4642: The next piece of the puzzle to keep KRAS in check
Article
Author: Drosten, Matthias ; Flores-Gómez, Alejandra A
KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows potent and selective anti-tumor activity across various models and synergizes with proteasome inhibitors. Responses have also been observed in patients during an ongoing phase 1 trial.
12 Dec 2023Cancer discovery
Drugging RAS: Moving Beyond KRASG12C
Article
Abstract:
Preliminary results from phase I trials respectively evaluating RMC-6236, a pan-RAS inhibitor, and HRS-4642, a KRASG12D inhibitor, indicate that both are safe and show promising signs of antitumor activity. These are just two of the candidate RAS therapies in a burgeoning development space as the field looks ahead to drugs that hit more than just KRASG12C.
100 Deals associated with HRS-4642
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| KRAS G12D mutation Solid Tumors | Phase 2 | CN | 05 Jul 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Jul 2024 | |
| Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | CN | 29 May 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05533463 (ESMO2023) Manual  | Phase 1 | KRAS G12D mutation Solid Tumors KRAS G12D | 18 | (advanced solid tumors harboring KRAS G12D mutation) | qsmjhjpanq(foritinhdg) = eykiwpajyl ijwknocizd (emllucxpvk ) View more | Positive | 22 Oct 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free